Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (Mirabegron)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02468830|
Recruitment Status : Completed
First Posted : June 11, 2015
Results First Posted : June 20, 2018
Last Update Posted : June 20, 2018
|Condition or disease||Intervention/treatment||Phase|
|Overactive Bladder Urinary Incontinence||Drug: mirabegron||Phase 3|
Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This condition comprises many urinary symptoms, such as urgency, increased daytime frequency of micturition, urge incontinence and nocturia. These symptoms are especially troublesome for the pediatric patients and their family since it causes embarrassment and it limits everyday activities and impairs children's development. Furthermore, serious complications are seen if this condition is not treated properly, as urinary tract infection, vesico-ureteral reflux and dysfunctional voiding. Antimuscarinic agents are the current pharmacologic mainstay for OAB. Many side effects are reported with the clinical use of antimuscarinics. Oxybutynin is the most widely antimuscarinic agent used in the pediatric population and is the only molecule approved by Health Canada for children with OAB. However, some patients have a suboptimal response to antimuscarinic and many experience side effects. Children with OAB therefore represent a disease population with a need for an alternative effective, safe and well-tolerated therapy to help manage the overactive detrusor, reducing or preventing incontinence.
Mirabegron, a β3-adrenoceptor (β3-AR) agonist approved for the treatment of OAB symptoms in the adult population, is the first of a new class of compounds with a different mechanism of action. The recommended starting dose of mirabegron is 25mg, which can be increased to 50mg, based on individual efficacy and tolerability. Side effects commonly reported with antimuscarinics were not observed more often with mirabegron than with placebo (headache 2.0%, dry mouth 2.0%, constipation 1.6%). Several Phase II and III studies have shown significant improvement in clinical OAB symptoms in adults treated with mirabegron with a favorable tolerability profile. Mirabegron has not been studied yet for pediatric patients and no recommendation with regards to its use has been issued by the manufacturer nor medical regulatory bodies.
A prospective open-label study, using an adjusted-dose regimen of mirabegron (25-50mg), including pediatric patients with refractory urinary incontinence due to OAB. This protocol was approved by the investigators' research ethics board. Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics are also included. primary end-point is efficacy toward urinary continence and secondary end-points are tolerability and safety. The patients/parents satisfaction will also be recorded.
After 8 to 12 weeks on the new medication, the possibility of up-titration will be assessed. Patients and parents will be questioned on compliance, tolerability and efficacy. If the patient is taking the medication ≥80% of the time, does not have any significant side effects and still has significant OAB symptoms, the investigators will offer a dose increase (Mirabegron 50mg daily). If accepted, the medication will be provided with instructions to report any new side effects.
Subjects will complete a 3-day voiding diary prior to each medical visit to assess the efficacy of the treatment and urotherapy. Visits will be done every 3 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||58 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder|
|Study Start Date :||April 2013|
|Actual Primary Completion Date :||January 2016|
|Actual Study Completion Date :||March 2016|
Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.
Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
Other Name: Myrbetriq
- Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron [ Time Frame: Participants will be followed for the duration of the study, up to 52 weeks ]Percent change in the frequency of urinary incontinence episodes as a Measure of Efficacy.
- Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron [ Time Frame: Participants will be followed for duration of the study, up to 52 weeks ]Change in mean bladder capacity from baseline to final visit based on voiding diary.
- Number of Participants With Cardio Vascular Safety [ Time Frame: Participants will be followed for the duration of the study, up to 52 weeks ]
Cardiovascular safety: mean difference in blood pressure (Variation in blood pressure: systolic ±20 mmHg, diastolic ±15 mmHg).
Parameters to be measure at each visit but particularly at visit 2 (Week 0, first dose on site), to be obtained before and 1 hour after taking the medication).
- Improved Quality of Life Using the Patient Perception of Bladder Condition (PPBC) Scale [ Time Frame: Participants will be followed for the duration of the study, up to 52 weeks ]
The Patient Perception of Bladder Condition (PPBC) scale on a 6-point score scale at baseline and final visit.
Explanation of possible answer:
- does not cause me any problems at all,
- causes me some very minor problems,
- causes me some minor problems,
- causes me (some) moderate problems,
- causes me severe problems,
- causes me many severe problems
- Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Mirabegron [ Time Frame: Participants will be followed for the duration of the study, up to 52 weeks ]Cardiovascular safety: mean difference in heart rate (variation in heart rate increase of more than 20%). Heart rate was taken at initiation of study drug, at each visit and at the study end.